Revised forecast
Fiscal year ending September 2026 · Full yearPrevious forecast published 13 November 2025The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
The revenue forecast was revised downward due to a decrease in the number of overseas patients, delays in launching new cell-processing services, and the deferral of the start of manufacturing for multiple CDMO contract projects. The operating income forecast was revised downward due to the decline in revenue and an increase in research and development expenses related to Stempeucel®. The ordinary income forecast was revised upward due to strong investment performance by investment limited partnerships and a reversal of the allowance for doubtful accounts following the partial recovery of long-term loans receivable.
| Item | Details |
|---|---|
| Net Sales | 943 Millions of yen → 821 Millions of yen（-12.9%） |
| Operating profit | -1,454 Millions of yen → -1,520 Millions of yen |
| Ordinary income | -1,449 Millions of yen → -1,360 Millions of yen |
| Profit attributable to owners of the parent | -1,453 Millions of yen → -1,426 Millions of yen |
| Net income per share | -5.49 yen → -5.19 yen |
| Fiscal Period Covered | Fiscal year ending September 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 13 November 2025 |
| Previous-period results | Revenue: ¥810 million; operating loss: ¥1,445 million; ordinary loss: ¥1,339 million; net loss: ¥1,362 million; net loss per share: ¥5.15 |
| Reason for the revision | The revenue forecast was revised downward due to a decrease in the number of overseas patients, delays in launching new cell-processing services, and the deferral of the start of manufacturing for multiple CDMO contract projects. The operating income forecast was revised downward due to the decline in revenue and an increase in research and development expenses related to Stempeucel®. The ordinary income forecast was revised upward due to strong investment performance by investment limited partnerships and a reversal of the allowance for doubtful accounts following the partial recovery of long-term loans receivable. |
Items this document does not state (3)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue is expected to decline due to a decrease in the number of overseas patients, delays in launching new cell-processing services, and the deferral of the start of manufacturing for multiple CDMO contract projects to the fiscal year ending September 2027. Operating income is expected to deteriorate as the decline in revenue and an increase in research and development expenses related to Stempeucel® outweigh reductions in general and administrative expenses, while ordinary income is expected to improve due to strong investment performance by investment limited partnerships and a reversal of the allowance for doubtful accounts following the partial recovery of long-term loans receivable.